Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
Key facts
- Who runs it
- HAII corp.ltd
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 96 people enrolled
- Started
- 14 Aug 2023
- Ended
- 24 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Software as a Medical device
- Record updated
- 19 September 2024
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- People can participate in this clinical trial only if following criteria are met
- Adults aged 19 years or older with a high school diploma or higher
- Disease groups according to the criteria below:; A person diagnosed with Generalized Anxiety Disorder (DSM-5 (ICD-10) code: 300.02 (F41.1)); Those who are classified as moderate or severe with 10 points or more through GAD-7; Those taking prescription drugs related to generalized anxiety disorder
- A group of disorders with generalized anxiety disorder, or a group of disorders with worry that is a major symptom of generalized anxiety disorder in any of the following criteria:; Those suffering from other anxiety disorders such as panic disorder and social anxiety disorder; Those suffering from major depressive disorder accompanied by worry, the main symptom of generalized anxiety disorder
- A person who fully understands the purpose, contents, and process of the clinical trial, agrees to participate, and signs the consent form in handwriting
Who cannot take part
- Receiving cognitive behavioral therapy for anxiety, depression or mood disorders, or participating in such therapy in the past 3 months
- In case of psychiatric symptoms or history (including schizophrenia, psychosis, bipolar disorder, epilepsy)
- In case of brain damage, cognitive impairment, or neurological disease
- Having a substance and alcohol use disorder
- If any of the following criteria is applicable, the person cannot participate in this clinical trial
- Those who cannot read the consent form
- Those who are inexperienced in using smartphones
- In case of intellectual disability
- Suicidal intent, suicidal ideation, or self-injurious behavior in the past 6 months
- Those who are registered in other clinical studies
- Other investigators judged that the conduct of this clinical trial was inappropriate
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder. The study will measure the therapeutic effects and safety of 'ANZEILAX' on symptoms of anxiety using pre- and post-treatment scores for generalized anxiety disorder and other physical, emotional, and cognitive symptoms of anxiety
The 2 groups in the trial
- Experimental GroupTreatment being tested
The general treatment of the standard treatment method and the test device that provides self-talk training based on acceptance and commitment therapy (ACT) are used concurrently for 10 weeks.
Treatment: Software as a Medical device
- Control GroupNo study treatment, for comparison
Treatment as usual (TAU) is a standard treatment for 10 weeks, which is the clinical trial period.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single Blind, Parallel Arm, Single Institution Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
- Publications
- Efficacy of a Smartphone-Based Digital Therapeutic (Anzeilax) in Generalized Anxiety Disorder: Randomized Controlled Trial.Journal of medical Internet research, 2025
- Record updated
- 19 September 2024